Patents by Inventor Kurt Hertogs
Kurt Hertogs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8574831Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.Type: GrantFiled: November 1, 2007Date of Patent: November 5, 2013Assignee: Virco N.V.Inventors: Pascale Alfons Rosa Dehertogh, Kurt Hertogs, Brendan Larder, Dechao Wang
-
Patent number: 8563236Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.Type: GrantFiled: January 13, 2009Date of Patent: October 22, 2013Assignee: Virco, N.V.Inventors: Kurt Hertogs, Brendan Larder, Rudi Pauwels
-
Publication number: 20100048563Abstract: The present invention concerns the compounds of formula (I) their N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites, wherein n is 1, 2 or 3; R1 is H, CN, halo, aminoC(?O), C(?O)OH, C1-4alkyloxyC(?O), C1-4alkylC(?O), mono- or di(C1-4alkyl)aminoC(?O), arylaminoC(?O), N-(aryl)-N—(C1-4alkyl)aminoC(?O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het1 or Het2; R2 is H, C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, wherein said C1-10alkyl, C2-10alkenyl and C3-7cycloalkyl may be optionally substituted; R3 is nitro, cyano, amino, halo, hydroxy, C1-4alkyloxy, hydroxyC(?O), aminoC(?O), C1-4alkyloxyC(?O), mono- or di(C1-4alkyl)aminoC(?O), C1-4alkylC(?O), methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, N-hydroxy-methanimidamidyl or Het1; for use as a medicine. The invention further relates to a novel subgroup of the compounds of formula (I), and to compositions comprising compounds of formula (I).Type: ApplicationFiled: August 25, 2009Publication date: February 25, 2010Inventors: Bart Rudolf Romanie KESTELEYN, Wim Van De Vreken, Natalie Maria Francisca Kindermans, Maxime Francis Jean-Marie Ghislain Canard, Kurt Hertogs, Eva Bettens, Veronique Corine Paul De Vroey, Dirk Edward Désiré Jochmans
-
Patent number: 7608726Abstract: The present invention concerns the compounds of formula (I) their N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites, wherein n is 1, 2 or 3; R1is H, CN, halo, aminoC(?O), C(?O)OH, C1-4alkyloxyC(?O), C1-4alkylC(?O), mono- or di(C1-4alkyl)aminoC(?O), arylaminoC(?O), N-(aryl)-N—(C1-4alkyl)aminoC(?O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het1 or Het2; R2 is H, C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, wherein said C1-10alkyl, C2-10alkenyl and C3-7cycloalkyl may be optionally substituted; R3 is nitro, cyano, amino, halo, hydroxy, C1-4alkyloxy, hydroxyC(?O), aminoC(?O), C1-4alkyloxyC(?O), mono- or di(C1-4alkyl)aminoC(?O), C1-4alkylC(?O), methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, N-hydroxy-methanimidamidyl or Het1; for use as a medicine. The invention further relates to a novel subgroup of the compounds of formula (I), and to compositions comprising compounds of formula (I).Type: GrantFiled: November 14, 2003Date of Patent: October 27, 2009Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Bart Rudolf Romanie Kesteleyn, Wim Van De Vreken, Natalie Maria Francisca Kindermans, Maxime Francis Jean-Marie Ghislain Canard, Kurt Hertogs, Eva Bettens, Veronique Corine Paul De Vroey, Dirk Edward Désiré Jochmans
-
Patent number: 7585870Abstract: This invention concerns HIV replication inhibitors of formula (I), the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.Type: GrantFiled: February 20, 2004Date of Patent: September 8, 2009Assignee: Tibotec BVBAInventors: Jerôme Emile Georges Guillemont, Elisabeth Thérese Jeanne Pasquier, Jan Heeres, Kurt Hertogs, Eva Bettens, Paulus Joannes Lewi, Marc René De Jonge, Lucien Maria Henricus Koymans, Frederik Frans Desiré Daeyaert, Hendrik Maarten Vinkers, Frank Xavier Jozef Herwig Arts
-
Publication number: 20090162867Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.Type: ApplicationFiled: January 13, 2009Publication date: June 25, 2009Inventors: Kurt Hertogs, Brendan Larder, Rudl Pauwels
-
Patent number: 7494768Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.Type: GrantFiled: May 30, 2000Date of Patent: February 24, 2009Assignee: Tibotec-Virco Virology BVBAInventors: Kurt Hertogs, Brendan Larder, Rudi Pauwels
-
Publication number: 20080286754Abstract: The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.Type: ApplicationFiled: November 1, 2007Publication date: November 20, 2008Inventors: Pascale Alfons Rosa DEHERTOGH, Kurt Hertogs, Brendan Larder, Dechao Wang
-
Patent number: 7442705Abstract: This invention concerns HIV replication inhibitors of formula (I), The N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.Type: GrantFiled: February 20, 2004Date of Patent: October 28, 2008Assignee: Tibotec Pharmaceuticals LtdInventors: Jerôme Emile Georges Guillemont, Elisabeth Thérese Jeanne Pasquier, Jan Heeres, Kurt Hertogs, Eva Bettens, Paulus Joannes Lewi, Marc René De Jonge, Lucien Maria Henricus Koymans, Frederik Frans Desiré Daeyaert, Hendrik Maarten Vinkers, Frank Xavier Jozef Herwig, legal representative, Paul Adriaan Jan Janssen
-
Patent number: 7429677Abstract: The present invention concerns a compound having the formula (I) a N-oxide form, a stereochemical isomer, racemic mixture, salt, prodrug, ester or metabolite thereof. It further relates to processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present entry inhibitors with anti-retroviral agents. It further relates to their use in assays as reference compounds or as reagents. The compounds of the present invention are useful for preventing or treating infection by HIV and for treating AIDS.Type: GrantFiled: March 11, 2003Date of Patent: September 30, 2008Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Marie-Pierre T. M. M. G De Bethune, Sandra De Meyer, Kurt Hertogs, Rong Jian Lu, Lieve Emma Jan Michiels, Abdellah Tahri, Dong Xie, Michael Eissenstat
-
Publication number: 20080234288Abstract: The present invention concerns sulfonamide derivatives having the general formula and N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs and esters thereof, wherein Q1 is —S— or —O—; R1 is hydrogen, C1-6alkyl, hydroxy, amino, halogen, aminoC1-4alkyl and mono- or di(C1-4alkyl)amino; R2 is hydrogen or C1-6alkyl; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or arylC1-4alkyl; R4 is hydrogen, C1-4alkyloxycarbonyl, carboxyl, optionally mono- or disubstituted aminocarbonyl, mono- or di(C1-4alkyl)aminocarbonyl, C3-7cycloalkyl, C2-6alkenyl, C2-6alkynyl or C1-6alkyl optionally substituted with one or more substituents each independently selected from aryl, Het1, Het2, C3-7cycloalkyl, C1-4alkyloxy-carbonyl, carboxyl, aminocarbonyl, mono- or di(C1-4alkyl)aminocarbonyl, aminosulfonyl, C1-4alkylS(?O)t, hydroxy, cyano, halogen or amino optionally mono- or di-substituted where the substituents are each independently selected from C1-4alkyl, aryl, arylC1-4alkyl, C3-7cycloalkyl, C3-7cycloaType: ApplicationFiled: September 30, 2004Publication date: September 25, 2008Inventors: Kenneth Alan Simmen, Koenraad Lodewijk August Van Acker, Piet Tom Bert Paul Wigerinck, Dominique Louis Nestor Ghislain Surleraux, Gery Karel Julia Dams, Ludo Maria Marcel Quirynen, Kurt Hertogs, Rudi Wilfried Jan Pauwels
-
Patent number: 7292944Abstract: The present invention concerns methods and systems for improving the accuracy of predicting resistance of a disease to a therapy. In one embodiment of the invention, mean and standard deviation (SD) values of fold change in normalized sensitivity, relative to a laboratory wild type standard pathogen or malignant cell are calculated to demonstrate that the patient samples display inherently different degrees of variation in susceptibility to each therapy. In another embodiment, the 2×SD value for each therapy is used as the cut-off between sensitive (within normal susceptible range) and resistant (above normal susceptible range).Type: GrantFiled: October 22, 2001Date of Patent: November 6, 2007Assignee: Virco BVBAInventors: Brendan Larder, Richard P. Harrigan, Kurt Hertogs
-
Publication number: 20070249655Abstract: The present invention concerns combinations comprising a compound of formula (I) the N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters or metabolites thereof, wherein n is 1, 2 or 3; R1 is H, CN, halo, aminoC(?O), C(?O)OH, C1-4alkyloxyC(?O), C1-4alkylC(?O), mono- or di(C1-4alkyl)aminoC(?O), arylaminoC(?O), N-(aryl)-N-(C1-4alkyl)aminoC(?O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het1 or Het2; R2 is H, C1-4alkyl, C2-10alkenyl, C3-7cycloalkyl, wherein said C1-10alkyl, C2-10alkenyl and C3-7cycloalkyl may be optionally substituted; R3 is nitro, cyano, amino, halo, hydroxy, C1-4alkyloxy, hydroxyC(?O), aminoC(?O), C1-4alkyloxyC(?O), mono- or di(C1-4alkyl)aminoC(?O), C1-4alkylC(?O), methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, N-hydroxy-methanimidamidyl or Het1; and another HIV inhibitor.Type: ApplicationFiled: May 17, 2005Publication date: October 25, 2007Inventors: Bart Kesteleyn, Wim Van De Vreken, Natalie Kindermans, Maxime Francis Canard, Kurt Hertogs, Eva Bettens, Veronique De Vroey, Dirk Jochmans, Piet Wigerinck, Abdellah Tahri, Jing Wang, Dominique Louis Surleraux
-
Publication number: 20070166747Abstract: The present invention concerns methods for measuring drug resistance by correlating genotypic information with phenotypic profiles. In one embodiment, a method for interpreting genotypic information is described wherein a genetic code is generated from a patient sample, a list of mutations known or suspect to play a role in the development of resistance to one or more drugs is obtained from the generated genetic code, a genotype database is interrogated for previous samples with similar mutations relating to said one or more drugs, a phenotype for said sample is located in a phenotype database, the mean change in inhibition is determined based on all the examples located in said phenotype database, a distribution of sensitivities of one or more drugs suitable for treating a specific indication is determined.Type: ApplicationFiled: March 6, 2007Publication date: July 19, 2007Applicant: Virco N.V.Inventors: Brendan Larder, Stuart Bloor, Kurt Hertogs, Pascale Dehertogh, Rudy Mortier
-
Patent number: 7206699Abstract: The present invention concerns methods for measuring drug resistance by correlating genotypic information with phenotypic profiles. In one embodiment, a method for interpreting genotypic information is described wherein a genetic code is generated from a patient sample, a list of mutations known or suspect to play a role in the development of resistance to one or more drugs is obtained from the generated genetic code, a genotype database is interrogated for previous samples with similar mutations relating to said one or more drugs, a phenotype for said sample is located in a phenotype database, the mean change in inhibition is determined based on all the examples located in said phenotype database, a distribution of sensitivities of one or more drugs suitable for treating a specific indication is determined.Type: GrantFiled: April 18, 2001Date of Patent: April 17, 2007Assignee: Virco N.V.Inventors: Brendan Larder, Stuart Bloor, Kurt Hertogs, Pascale Alfons Rosa Dehertogh, Rudy Jean Marc Mortier
-
Publication number: 20060286547Abstract: The present invention relates to a multi-well assay for identifying a compound inhibiting the replication cycle of a micro-organism, for example, HIV, and to an apparatus for carrying out an assay according to the present invention. The invention further relates to compounds identifiable with an assay according to the invention and pharmaceutical compositions comprising a therapeutically effective amount of such compounds. The identified compounds may be used as medicaments, and in particular for the manufacture of a medicament for treating infectious diseases and in method for treating infectious diseases including AIDS.Type: ApplicationFiled: September 20, 2004Publication date: December 21, 2006Inventors: Koenraad Van Acker, Lieve Bunkens, Gery Dams, Kurt Hertogs, Tania Ivens, Erik Nijs
-
Publication number: 20060194804Abstract: This invention concerns HIV replication inhibitors of formula (I), The N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.Type: ApplicationFiled: February 20, 2004Publication date: August 31, 2006Inventors: Jerome Guillemont, Elisabeth Pasquier, Jan Heeres, Kurt Hertogs, Eva Bettens, Paulus Lewi, Marc De Jonge, Lucien Maria Koymans, Frederik Daeyaert, Hendrik Vinkers, Adriaan Janssen, Frank Zavier Jozef Arts
-
Publication number: 20060173000Abstract: The present invention concerns the compounds of formula (I) their N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites, wherein n is 1, 2 or 3; R1 is H, CN, halo, aminoC(?O), C(?O)OH, C1-4alkyloxyC(?O), C1-4alkylC(?O), mono- or di(C1-4alkyl)aminoC(?O), arylaminoC(?O), N-(aryl)-N—(C1-4alkyl)aminoC(?O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het, or Het2; R2 is H, C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, wherein said C1-10alkyl, C2-10alkenyl and C3-7cycloalkyl may be optionally substituted; R3 is nitro, cyano, amino, halo, hydroxy, C1-4alkyloxy, hydroxyC(?O), aminoC(?O), C1-4alkyloxyC(?O), mono- or di(C1-4alkyl)aminoC(?O), C1-4alkylC(?O), methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, N-hydroxy-methanimidamidyl or Het1; for use as a medicine. The invention further relates to a novel subgroup of the compounds of formula (I), and to compositions comprising compounds of formula (I).Type: ApplicationFiled: November 14, 2003Publication date: August 3, 2006Inventors: Bart Kesteleyn, Wim Van De Vreken, Natalie Kindermans, Maxime Francis Canard, Kurt Hertogs, Eva Bettens, Veronique Corine De Vroey, Dirk Jochmans
-
Publication number: 20060142571Abstract: This invention concerns HIV replication inhibitors of formula (I), the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them.Type: ApplicationFiled: February 20, 2004Publication date: June 29, 2006Inventors: Jerome Guillemont, Elisabeth Therese Pasquier, Jan Heeres, Kurt Hertogs, Eva Bettens, Paulus Lewi, Marc De Jonge, Lucien Maria Koymans, Frederik Frans Daeyaert, Hendrik Vinkers, Frank Xavier Jozef Arts
-
Publication number: 20060025594Abstract: The present invention concerns a compound having the formula (I) a N-oxide form, a stereochemical isomer, racemic mixture, salt, prodrug, ester or metabolite thereof. It further relates to processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present entry inhibitors with anti-retroviral agents. It further relates to their use in assays as reference compounds or as reagents. The compounds of the present invention are useful for preventing or treating infection by HIV and for treating AIDS.Type: ApplicationFiled: March 11, 2003Publication date: February 2, 2006Applicant: TIBOTEC Pharmaceuticals Ltd.Inventors: Marie-Pierre De Bethune, Sandra De Meyer, Kurt Hertogs, Rong Lu, Lieve Michiels, Abdellah Tahri, Dong Xie, Michael Eissenstat